Growth hormone doesn’t release on demand. The pituitary fires in pulses, responds to specific molecular signals, and ignores everything else. Researchers studying this system pay close attention to which compounds actually reach those receptors intact. The cjc-1295 canada sits at the centre of this inquiry because it engages the pituitary through two receptor pathways rather than one, which changes how absorption itself gets interpreted.
Why does oral delivery fail?
Swallowing a peptide accomplishes very little. The stomach treats amino acid chains as food. Proteolytic enzymes cleave the bonds holding those chains together long before anything crosses into circulation. By the time digestion finishes, whatever biological activity the compound was supposed to carry is gone.
Subcutaneous injection sidesteps this entirely. Tissue beneath the skin doesn’t expose compounds to digestive enzymes. It holds them in a localised depot while capillary networks gradually pull the peptide into systemic circulation. The absorption is slower and steadier than intravenous delivery, which actually suits pulsatile hormone systems better than a sudden spike would.
Moving through tissue
Molecular weight shapes how easily a peptide crosses biological barriers. Smaller chains navigate interstitial fluid and capillary walls with less resistance than large protein structures do. Both components of this blend fall within ranges that permit capillary crossing without significant loss.
Once circulating, peptides don’t bind indiscriminately. Receptor distribution across different tissue types determines where each compound actually lands. The anterior pituitary carries a concentration of receptors directly relevant to growth hormone regulation, which is where the real specificity of this blend becomes clear.
- The GHRH receptor on somatotroph cells responds to growth hormone-releasing hormone analogues
- The GHS-R receptor responds to ghrelin-mimicking secretagogues through a separate intracellular mechanism
- Activating both simultaneously generates a combined release exceeding what single-pathway stimulation produces
CJC-1295 without DAC targets the first. Its structure mirrors endogenous GHRH closely enough to bind and trigger a secretory pulse. Without the drug affinity complex extending its half-life artificially, the compound clears within roughly 30 minutes. Keeping the signal short helps keep it sharp rather than sustained.
Ipamorelin targets the second. At research concentrations, its receptor selectivity is notably narrow, engaging GHS-R without meaningfully pulling cortisol or prolactin into the response. That restraint separates it from most compounds in the secretagogue category.
After the pituitary fires
Released growth hormone doesn’t act directly on muscle or bone. After passing through the liver, the signal is converted into IGF-1, also called insulin-like growth factor 1. IGF-1 then distributes outward to peripheral tissues carrying the appropriate receptors. Adipose tissue, skeletal muscle, and bone all fall within that group.
The full absorption sequence runs longer than the injection site suggests. Subcutaneous entry feeds systemic circulation. Circulation delivers peptides to pituitary receptors. Receptor binding triggers hormone secretion. Secretion drives hepatic IGF-1 synthesis. IGF-1 reaches peripheral targets last.
Each step is contingent on the one before it. There is no shortcut to hormone absorption, regardless of what initiates it. Understanding absorption requires following the entire chain, not just its starting point.